The Lumipulse G β-Amyloid Ratio (1-42/1-40) test is intended to be used as an aid in adults 55 years of age and older presenting with cognitive impairment who are being evaluated for Alzheimer disease and other causes of cognitive decline.
Researchers sought to assess the clinical prevalence of Alzheimer disease in patients with leprosy, also known as Hansen’s disease, and inflammasome activity.
Researchers sought to examine whether individuals with familial hypercholesterolemia are at a heightened risk for dementia and whether statin use is tied to dementia risk.